Changes in the quality of life of early breast cancer patients and comparison with the normative Slovenian population
, , und | 21. Juni 2023
Über diesen Artikel
Article Category: Research Article
Online veröffentlicht: 21. Juni 2023
Seitenbereich: 211 - 219
Eingereicht: 27. Nov. 2022
Akzeptiert: 26. Dez. 2022
DOI: https://doi.org/10.2478/raon-2023-0019
Schlüsselwörter
© 2023 Cvetka Grasic Kuhar et al., published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
FIGURE 1.
FIGURE 2.
Clinical characteristics of participants at beginning of the study and after one-year post-chemotherapy
| Tumour stage | ||
| T1 | 6 (45.1) | 32 (44.4) |
| T2 | 43 (42.2) | 33 (45.8) |
| T3 | 13 (12.7) | 7 (9.7) |
| Lymph node stage | ||
| N0 | 43 (42.2) | 31 (43.1) |
| N1 | 38 (37.3) | 30 (41.7) |
| N2 | 12 (11.8) | 9 (12.5) |
| N3 | 9 (8.8) | 2 (2.8) |
| Tumour subtype | ||
| Luminal A-like | 12 (11.8) | 7 (9.7) |
| Luminal B-like | 47 (46.1) | 35 (48.6) |
| Luminal B HER2 positive | 19 (18.6) | 14 (19.4) |
| HER2 positive | 8 (7.8) | 6 (8.3) |
| Triple-negative | 16 (15.7) | 10 (13.9) |
| Type of surgery | ||
| Breast-conserving surgery + Sentinel node biopsy | 37 (36.3) | 28 (38.9) |
| Breast-conserving surgery + Axillary dissection | 14 (13.7) | 11 (15.3) |
| Mastectomy + Sentinel node biopsy | 23 (22.5) | 15 (20.8) |
| Mastectomy + Axillary dissection | 28 (27.5) | 18 (25.0) |
| Breast reconstruction | ||
| None | 78 (76.5) | 55 (76.4) |
| Deep inferior flap | 13 (12.7) | 10 (13.9) |
| Tissue expander, followed by silicone implant | 11 (10.8) | 7 (9.7) |
| Chemotherapy type | ||
| Anthracyclines and taxanes | 70 (68.7) | 51 (70.8) |
| Anthracyclines only | 19 (18.6) | 13 (18.1) |
| Taxanes only | 10 (9.8) | 6 (8.3) |
| CMF | 3 (2.9) | 2 (2.8) |
| Anti-HER2 therapy | 27 (26.4) | 20 (27.8) |
| Adjuvant endocrine therapy | 78 (76.5) | 57 (79.2) |
| Radiotherapy | 81 (79.4) | 59 (81.9) |
Patient-reported outcomes presented by EORTC C30 Summary Score (C-30 SumSc) and global health status/quality of life (GHS) at inclusion (beginning of chemotherapy), one-year post-chemotherapy, and the difference among both times
| n | mean | Mean (95% CI) | p | Mean (95% CI) | p | Mean (95% CI) | p | |
| C-30 SumSc | 70 | 90.9 | 88.5 (86.1, 90.8) | 0.04 | 82 (78.4, 85.5) | < 0.001 | −6.5 (−9.6, −3.4) | < 0.001 |
| GHS | 71 | 72.7 | 71.1 (66.7, 75.6) | 0.50 | 69.6 (65, 74.2) | 0.19 | −1.5 (−6.6, 3.5) | 0.55 |